ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,807.27
-0.41%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. UroGen Pharma Ltd (URGN)

  7. UroGen Pharma Ltd (URGN) Noticias

URGN

UroGen Pharma (URGN)

UroGen Pharma Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:URGN
FechaHoraFuenteTítuloSímboloCompañía
13/05/202407:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:URGNUroGen Pharma Ltd
13/05/202407:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
13/05/202407:00Business WireUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business HighlightsNASDAQ:URGNUroGen Pharma Ltd
07/05/202407:00Business WireUroGen Pharma to Participate at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
05/05/202411:20Business WireNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction TherapyNASDAQ:URGNUroGen Pharma Ltd
04/05/202414:20Business WireUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024NASDAQ:URGNUroGen Pharma Ltd
04/05/202410:50Business WireNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal TrialNASDAQ:URGNUroGen Pharma Ltd
03/05/202407:00Business WireUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024NASDAQ:URGNUroGen Pharma Ltd
17/04/202411:02Business WireUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
15/04/202407:00Business WireUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
03/04/202407:00Business WireUroGen Pharma Files Patent Infringement Action Against Teva PharmaceuticalsNASDAQ:URGNUroGen Pharma Ltd
14/03/202407:00Business WireUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102NASDAQ:URGNUroGen Pharma Ltd
08/03/202407:00Business WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
04/03/202407:00Business WireUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024NASDAQ:URGNUroGen Pharma Ltd
26/02/202407:00Business WireUroGen Pharma to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:URGNUroGen Pharma Ltd
12/02/202416:47Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
02/02/202418:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
01/02/202409:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
24/01/202407:00Business WireUroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102NASDAQ:URGNUroGen Pharma Ltd
17/01/202407:00Business WireUroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
11/01/202407:00Business WireUroGen Pharma to Participate in the B. Riley Healthcare ConferenceNASDAQ:URGNUroGen Pharma Ltd
14/11/202315:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:URGNUroGen Pharma Ltd
14/11/202307:00Business WireUroGen Pharma Reports Third Quarter 2023 Financial ResultsNASDAQ:URGNUroGen Pharma Ltd
13/11/202307:00Business WireUroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic OncologyNASDAQ:URGNUroGen Pharma Ltd
07/11/202307:00Business WireUroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023NASDAQ:URGNUroGen Pharma Ltd
03/10/202307:00Business WireFollowing Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024NASDAQ:URGNUroGen Pharma Ltd
17/09/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:URGNUroGen Pharma Ltd
11/09/202306:00GlobeNewswire Inc.Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of DirectorsNASDAQ:URGNUroGen Pharma Ltd
08/09/202315:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:URGNUroGen Pharma Ltd
31/08/202307:00Business WireUroGen Pharma to Present at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:URGN

Su Consulta Reciente

LSE
BK42
Hsbc Bk.25
COIN
ETHDETH
BIT
UB48HS
Unicredit Bank
COIN
ETRTUSD
USOTC
CTTQF
Costa (PK)
LSE
73KF
Hsbc Bk.24
ASX
WNI
USOTC
GRDDY
Grand City Properties (PK)
LSE
YL79
Hsbc Bk. 27
ASX
PAF
PM Capital Asian Opportu...
USOTC
GRRP
Granite Broadcasting (CE)
USOTC
GZMDF
Guanze Medical Informati... (PK)
TSX
GGA
Goldgroup Mining
COIN
QECNUSD
COIN
LOCKETH
Meridian Network
COIN
KTCNUSD
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados